Dodge & Cox Sells 1,087,377 Shares of Haleon PLC Sponsored ADR $HLN

Dodge & Cox trimmed its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 0.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 154,384,622 shares of the company’s stock after selling 1,087,377 shares during the period. Dodge & Cox owned about 3.47% of Haleon worth $1,384,830,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. SOA Wealth Advisors LLC. lifted its stake in shares of Haleon by 60.5% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company’s stock valued at $28,000 after acquiring an additional 1,170 shares during the last quarter. Citizens National Bank Trust Department grew its position in Haleon by 167.4% during the 3rd quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company’s stock worth $29,000 after acquiring an additional 2,051 shares during the last quarter. Atlantic Union Bankshares Corp increased its stake in Haleon by 293.7% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock worth $33,000 after purchasing an additional 2,758 shares during the period. Geneos Wealth Management Inc. lifted its position in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after purchasing an additional 1,203 shares during the last quarter. Finally, Mather Group LLC. bought a new stake in Haleon in the third quarter valued at approximately $52,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. HSBC raised shares of Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft cut shares of Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $12.33.

Haleon Stock Performance

Shares of HLN opened at $10.05 on Friday. The company has a 50-day simple moving average of $10.50 and a two-hundred day simple moving average of $9.86. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The firm has a market capitalization of $44.73 billion, a PE ratio of 25.76 and a beta of 0.18. Haleon PLC Sponsored ADR has a one year low of $8.71 and a one year high of $11.42.

Haleon Dividend Announcement

The company also recently announced a dividend, which will be paid on Thursday, May 14th. Stockholders of record on Friday, April 10th will be paid a $0.1307 dividend. This represents a dividend yield of 251.0%. The ex-dividend date is Friday, April 10th. Haleon’s dividend payout ratio (DPR) is presently 28.21%.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.